Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Commentary

A milestone for hepatitis C virus research: A virus generated in cell culture is fully viable invivo

Jens Bukh and Robert H. Purcell
  1. *Hepatitis Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; and
  2. †Department of Infectious Diseases, Hvidovre University Hospital, 2650 Hvidovre, Denmark

See allHide authors and affiliations

PNAS March 7, 2006 103 (10) 3500-3501; https://doi.org/10.1073/pnas.0600551103
Jens Bukh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jbukh@niaid.nih.gov jens.bukh@hh.hosp.dk
Robert H. Purcell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease in the United States, and the Centers for Disease Control has predicted that ≈10,000 Americans die annually from this disease. Since the discovery of HCV in 1989, basic research on this important pathogen has been difficult because of the lack of a robust cell-culture system. Thus, the recent development of a cell culture resulting in production of significant levels of infectious virus particles (1–3) will without doubt lead to rapid progress in our understanding of the HCV viral life cycle and, it is hoped, development of better therapies. The development of molecular clones of strain H77 (genotype 1a) infectious for chimpanzees in 1997 was an important initial advance, but these clones and subsequent infectious clones of other genotype strains did not produce viruses in cell culture (4–7). Another critical advance was the development of subgenomic replicons in 1999 that permitted studies of RNA replication (8). Efficient replication, however, depended on adaptive mutations (9, 10). In 2003, Kato et al. (11) observed that the WT JFH1 strain of HCV, belonging to genotype 2a, replicated to high levels in the replicon system. Subsequently, in 2005, Wakita and coworkers (2) demonstrated that RNA transcripts from the full-length JFH1 genome could produce viruses in a human liver hepatoma cell line (Huh-7 cells), and it was demonstrated by Chisari and coworkers (3) that this system could be developed to generate relatively high titers of HCV. In a different approach, Rice and coworkers (1) developed a chimeric genome in which the structural genes (C, E1, and E2), p7, and NS2 from an infectious clone of another genotype 2a strain (strain HC-J6) (6) were inserted into the subgenomic replicon of the JFH1 strain and demonstrated that RNA transcripts from this full-length chimeric genome could produce relatively high titers of HCV. In the current issue of PNAS, a study by Lindenbach et al. (12) demonstrated that chimeric J6/JFH1 viruses generated in vitro were fully viable also in vivo, as tested in chimpanzees and in SCID-uPA mice with human liver grafts, and that virus recovered from infected animals efficiently infected naïve Huh-7 cells. An overview of this important study is shown in Fig. 1. Therefore, it appears that not only has a cell-culture system been developed for HCV, but this system produces viruses that are biologically relevant.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Generation of J6/JFH1 viruses in cell culture and demonstration of their infectivity in vivo. Diagram showing study design and results in Lindenbach et al. (12). RNA transcripts from the chimeric genome were transfected into Huh-7.5 cells, and filtered supernatant was used to infect naïve Huh-7.5 cells. The immunostaining shown was performed with a mouse monoclonal NS5A antibody (1). Titrated virus from a virus stock was used to inoculate two chimpanzees i.v. and two SCID-uPA mice with a human liver graft i.p. Transfer of plasma from one of these viremic mice resulted in HCV infection in a third mouse. The specific infectivity (ratio of infectivity titer to RNA titer) was determined in naïve Huh-7 cells for chimpanzee and mouse serum containing the J6/JFH1 chimeric virus. TCID50, tissue culture 50% infective dose. Figure adapted, in part, from Lindenbach et al. (1).

The chimpanzee model is the only animal model available for HCV that permits studies of infectivity and pathogenesis (reviewed in ref. 13). The course of infection observed with the J6/JFH1 viruses derived from cell culture was similar to experimental acute infections with other HCV strains, with early appearance of viremia, peak viral titers of 104 to 105 units/ml, seroconversion, and induction of intrahepatic innate and adaptive immune responses. Neither of the two chimpanzees developed clear evidence of acute viral hepatitis, but that has also been observed in animals infected with WT virus. In 2001, Mercer et al. (14) introduced a mouse model that could be used to test the infectivity of HCV. In this SCID-uPA mouse, degenerated mouse hepatocytes are replaced by primary human hepatocytes (14, 15). It is a difficult model, in part because of high mortality and the need for fresh primary hepatocytes for engraftment (reviewed in ref. 16). However, if the mice have a successful graft as measured by a human albumin level of >1 mg/ml, they appear to be readily susceptible to HCV. Again in this animal model, the J6/JFH1 viruses behaved as WT virus and reached titers of 106 to 107 units/ml. Overall, therefore, the conclusion that these cell-culture-derived viruses are fully viable in vivo is justified. It will be important to confirm by sequence analysis that the virus recovered from the animals did not acquire adaptive mutations but the kinetics observed in the animals, and the fact that these viruses could readily infect naïve Huh-7 cells would suggest that adaptation did not play a major role.

As mentioned, efficient replication in Huh-7 cells of replicons of most HCV strains depends on adaptive mutations located at various sites in the nonstructural proteins (reviewed in ref. 17). It was previously demonstrated that such mutations severely attenuate viability of full-length genomes in chimpanzees (18) and also interfere with virus production in vitro (19). The exception, however, was the JFH1 strain, where the WT sequence apparently replicated to high levels in the replicon system. Two observations, however, suggest that the JFH1 full-length genome might be attenuated in vitro and in vivo. First, the JFH1 genome apparently has a delayed kinetics of virus release (2, 3, 12, 19), and it will be important to determine whether the JFH1 virus that eventually spreads efficiently in cell culture has acquired adaptive mutations. Second, the JFH1 virus collected from transfected Huh-7 cells resulted in an attenuated infection in a chimpanzee with low viremia titers, early viral clearance, and no seroconversion (2). The JFH1 and J6/JFH1 genomes have identical untranslated regions and NS3 through NS5B genes. The C, E1, E2, p7, and NS2 genes in the J6/JFH1 genome originate from a clone that was previously shown to be infectious in vivo (6). Thus the fact that the J6/JFH1 genome appears to be fully viable would suggest that the JFH1 full-length sequence might have sequences in the C through NS2 genes that are attenuating in vitro and in vivo. The fact that a chimera consisting of two different strains of the same genotype is highly replication-competent in vivo is somewhat surprising, in particular because the chimeric NS2–NS3 junction contains the NS2–NS3 autoprotease. Further studies are needed to determine whether the chimeric J6/JFH1 virus eventually acquires mutations that might further optimize replication of this cell-culture-derived virus.

A very intriguing observation was made by Lindenbach et al. (12) on the relative specific infectivity, as determined by comparing the infectivity titer in Huh-7 cells with the HCV genome titers of cell-cultured viruses from Huh-7 cells and those recovered from chimpanzees and SCID-uPA mice grafted with human hepatocytes (Fig. 1). The J6/JFH1 viruses recovered from animals had a specific infectivity that was 10- to 100-fold greater than viruses recovered from infected Huh-7 cells. This higher infectivity of animal-derived viruses was lost after reculture in Huh-7 cells. The difference in specific infectivity of these viruses was reflected by a difference in their buoyant density, with the animal-derived viruses having a lower density. This finding raises the possibility that specific proteins released by human or chimpanzee hepatocytes enhance infectivity of HCV. This phenomenon has recently been observed in the HCV pseudovirus system, in which the entry of retroviral pseudovirus particles bearing the envelope proteins of HCV was found to be enhanced by serum from chimpanzees and humans, human lipoproteins, and human apolipoproteins (20–23). Thus, it is a possibility that such lipoproteins and apolipoproteins might also enhance the infectivity of HCV in cell culture.

The development of the J6/JFH1 culture system by Lindenbach et al. (1) that produces viruses that are fully viable in vivo (12) is a major accomplishment. This culture system is still limited to this particular genotype 2a strain, and even the full-length HC-J6 genome does not replicate in Huh-7 cells. Thus, it will be important to develop this system for HCV strains representing all six major genotypes of HCV. Such diversity will probably be essential in the testing of new virus-specific antivirals, such as protease and polymerase inhibitors, which most likely will have different efficacies against different viral sequences. Alternatively, other JFH1 chimeric viruses that contain the C through NS2 sequence from other strains could be developed and would be sufficient for studying virus neutralization and specific mechanisms of how HCV enters the host cell. Another limitation of the current cell-culture system is its dependence on a single cell line, which is a hepatoma cell line known to have numerous genetic defects compared with hepatocytes. Such defects could lead, in particular, to data on virus–host interactions that are not biologically relevant. Finally, to consider this cell-culture system for the development of an inactivated whole virus vaccine, it would be critical to identify cell lines, approved for vaccine production, in which HCV can grow to even higher titers than is currently observed in Huh-7 cells. Thus, although the HCV research field has reached an important milestone with the development of a true cell-culture system that permits classical virological studies, new developments are required to expand research beyond one virus and one cell.

Footnotes

  • ‡To whom correspondence should be addressed. E-mail: jbukh{at}niaid.nih.gov or jens.bukh{at}hh.hosp.dk
  • Author contributions: J.B. and R.H.P. wrote the paper.

  • Conflict of interest statement: No conflicts declared.

  • See companion article on page 3805.

  • © 2006 by The National Academy of Sciences of the USA

References

  1. ↵
    1. Lindenbach B. D. ,
    2. Evans M. J. ,
    3. Syder A. J. ,
    4. Wolk B. ,
    5. Tellinghuisen T. L. ,
    6. Liu C. C. ,
    7. Maruyama T. ,
    8. Hynes R. O. ,
    9. Burton D. R. ,
    10. McKeating J. A. ,
    11. Rice C. M.
    (2005) Science 309:623–626, pmid:15947137.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Wakita T. ,
    2. Pietschmann T. ,
    3. Kato T. ,
    4. Date T. ,
    5. Miyamoto M. ,
    6. Zhao Z. ,
    7. Murthy K. ,
    8. Habermann A. ,
    9. Krausslich H. G. ,
    10. Mizokami M. ,
    11. et al.
    (2005) Nat. Med 11:791–796, pmid:15951748.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Zhong J. ,
    2. Gastaminza P. ,
    3. Cheng G. ,
    4. Kapadia S. ,
    5. Kato T. ,
    6. Burton D. R. ,
    7. Wieland S. F. ,
    8. Uprichard S. L. ,
    9. Wakita T. ,
    10. Chisari F. V.
    (2005) Proc. Natl. Acad. Sci. USA 102:9294–9299, pmid:15939869.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Kolykhalov A. A. ,
    2. Agapov E. V. ,
    3. Blight K. J. ,
    4. Mihalik K. ,
    5. Feinstone S. M. ,
    6. Rice C. M.
    (1997) Science 277:570–574, pmid:9228008.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Yanagi M. ,
    2. Purcell R. H. ,
    3. Emerson S. U. ,
    4. Bukh J.
    (1997) Proc. Natl. Acad. Sci. USA 94:8738–8743, pmid:9238047.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Yanagi M. ,
    2. Purcell R. H. ,
    3. Emerson S. U. ,
    4. Bukh J.
    (1999) Virology 262:250–263, pmid:10489358.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Yanagi M. ,
    2. St. Claire M. ,
    3. Shapiro M. ,
    4. Emerson S. U. ,
    5. Purcell R. H. ,
    6. Bukh J.
    (1998) Virology 244:161–172, pmid:9581788.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lohmann V. ,
    2. Korner F. ,
    3. Koch J. ,
    4. Herian U. ,
    5. Theilmann L. ,
    6. Bartenschlager R.
    (1999) Science 285:110–113, pmid:10390360.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Blight K. J. ,
    2. Kolykhalov A. A. ,
    3. Rice C. M.
    (2000) Science 290:1972–1974, pmid:11110665.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Lohmann V. ,
    2. Korner F. ,
    3. Dobierzewska A. ,
    4. Bartenschlager R.
    (2001) J. Virol 75:1437–1449, pmid:11152517.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Kato T. ,
    2. Date T. ,
    3. Miyamoto M. ,
    4. Furusaka A. ,
    5. Tokushige K. ,
    6. Mizokami M. ,
    7. Wakita T.
    (2003) Gastroenterology 125:1808–1817, pmid:14724833.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Lindenbach B. D. ,
    2. Meuleman P. ,
    3. Ploss A. ,
    4. Vanwolleghem T. ,
    5. Syder A. J. ,
    6. McKeating J. A. ,
    7. Lanford R. E. ,
    8. Feinstone S. M. ,
    9. Major M. E. ,
    10. Leroux-Roels G. ,
    11. et al.
    (2006) Proc. Natl. Acad. Sci. USA 103:3805–3809, pmid:16484368.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Bukh J.
    (2004) Hepatology 39:1469–1475, pmid:15185284.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Mercer D. F. ,
    2. Schiller D. E. ,
    3. Elliott J. F. ,
    4. Douglas D. N. ,
    5. Hao C. ,
    6. Rinfret A. ,
    7. Addison W. R. ,
    8. Fischer K. P. ,
    9. Churchill T. A. ,
    10. Lakey J. R. ,
    11. et al.
    (2001) Nat. Med 7:927–933, pmid:11479625.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Meuleman P. ,
    2. Libbrecht L. ,
    3. De Vos R. ,
    4. de Hemptinne B. ,
    5. Gevaert K. ,
    6. Vandekerckhove J. ,
    7. Roskams T. ,
    8. Leroux-Roels G.
    (2005) Hepatology 41:847–856, pmid:15791625.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Kneteman N. M. ,
    2. Mercer D. F.
    (2005) Hepatology 41:703–706, pmid:15789361.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Bartenschlager R. ,
    2. Lohmann V.
    (2001) Antiviral Res 52:1–17, pmid:11530183.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bukh J. ,
    2. Pietschmann T. ,
    3. Lohmann V. ,
    4. Krieger N. ,
    5. Faulk K. ,
    6. Engle R. E. ,
    7. Govindarajan S. ,
    8. Shapiro M. ,
    9. St. Claire M. ,
    10. Bartenschlager R.
    (2002) Proc. Natl. Acad. Sci. USA 99:14416–14421, pmid:12391335.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Bartenschlager R. ,
    2. Pietschmann T.
    (2005) Proc. Natl. Acad. Sci. USA 102:9739–9740, pmid:15998731.
    OpenUrlFREE Full Text
  20. ↵
    1. Bartosch B. ,
    2. Verney G. ,
    3. Dreux M. ,
    4. Donot P. ,
    5. Morice Y. ,
    6. Penin F. ,
    7. Pawlotsky J. M. ,
    8. Lavillette D. ,
    9. Cosset F. L.
    (2005) J. Virol 79:8217–8229, pmid:15956567.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Meunier J.-C. ,
    2. Engle R. E. ,
    3. Faulk K. ,
    4. Zhao M. ,
    5. Bartosch B. ,
    6. Alter H. ,
    7. Emerson S. U. ,
    8. Cosset F.-L. ,
    9. Purcell R. H. ,
    10. Bukh J.
    (2005) Proc. Natl. Acad. Sci. USA 102:4560–4565, pmid:15767578.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Voisset C. ,
    2. Callens N. ,
    3. Blanchard E. ,
    4. Op De Beeck A. ,
    5. Dubuisson J. ,
    6. Vu-Dac N.
    (2005) J. Biol. Chem 280:7793–7799, pmid:15632171.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Lavillette D. ,
    2. Morice Y. ,
    3. Germanidis G. ,
    4. Donot P. ,
    5. Soulier A. ,
    6. Pagkalos E. ,
    7. Sakellariou G. ,
    8. Intrator L. ,
    9. Bartosch B. ,
    10. Pawlotsky J. M. ,
    11. Cosset F. L.
    (2005) J. Virol 79:6023–6034, pmid:15857988.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A milestone for hepatitis C virus research: A virus generated in cell culture is fully viable invivo
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A milestone for hepatitis C virus research: A virus generated in cell culture is fully viable invivo
Jens Bukh, Robert H. Purcell
Proceedings of the National Academy of Sciences Mar 2006, 103 (10) 3500-3501; DOI: 10.1073/pnas.0600551103

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
A milestone for hepatitis C virus research: A virus generated in cell culture is fully viable invivo
Jens Bukh, Robert H. Purcell
Proceedings of the National Academy of Sciences Mar 2006, 103 (10) 3500-3501; DOI: 10.1073/pnas.0600551103
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley

Related Article

  • Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
    - Feb 16, 2006
Proceedings of the National Academy of Sciences of the United States of America: 103 (10)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Smoke emanates from Japan’s Fukushima nuclear power plant a few days after tsunami damage
Core Concept: Muography offers a new way to see inside a multitude of objects
Muons penetrate much further than X-rays, they do essentially zero damage, and they are provided for free by the cosmos.
Image credit: Science Source/Digital Globe.
Water from a faucet fills a glass.
News Feature: How “forever chemicals” might impair the immune system
Researchers are exploring whether these ubiquitous fluorinated molecules might worsen infections or hamper vaccine effectiveness.
Image credit: Shutterstock/Dmitry Naumov.
Venus flytrap captures a fly.
Journal Club: Venus flytrap mechanism could shed light on how plants sense touch
One protein seems to play a key role in touch sensitivity for flytraps and other meat-eating plants.
Image credit: Shutterstock/Kuttelvaserova Stuchelova.
Illustration of groups of people chatting
Exploring the length of human conversations
Adam Mastroianni and Daniel Gilbert explore why conversations almost never end when people want them to.
Listen
Past PodcastsSubscribe
Panda bear hanging in a tree
How horse manure helps giant pandas tolerate cold
A study finds that giant pandas roll in horse manure to increase their cold tolerance.
Image credit: Fuwen Wei.

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Cozzarelli Prize
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490